Marigdalia K. Ramirez-Fort, MD is the ACNM Intern (2023-2025)

Marigdalia Ramirez-Fort, MD earned her undergraduate degree at Lehigh University and medical degree at Ponce Health Sciences University. My General Surgery internship was completed at the University of Pittsburgh Medical Center. Since then, I trained in Radiation Oncology at the SUNY Downstate Health Sciences University and Medical University of South Carolina, jointly with a postdoctoral research fellowship in Urological Oncology at Weill Cornell Medicine. In July 2022 I commenced residency training in Nuclear Medicine at the University of California Los Angeles-Veterans Affairs program, where I became the first resident from my program to be awarded the ACNM Internship. Due to licensing issues, I am now seeking to transfer to a program in New York or Puerto Rico (where I am licensed to practice medicine) to complete training.

To date, I’ve authored more than 70 peer-reviewed articles, abstracts and book chapters, and have served as the lead editor for a textbook on human papillomavirus for Karger Publishers. Now, I serve as Co-Editor for the Frontier in Medicine Series Issue: ‘Women in Science—Nuclear Medicine 2024’. I have experience in running approximately 30 investigator-initiated or pharmaceutical sponsored clinical trials as sub-, co- or principal investigator. The latter portion of these trials involved the development of the theragnostic target, PSMA, encoded by the FOLH1 gene. Throughout my training and career as a physician-scientist, I have been involved in a wide range of preclinical and clinical research, including studies involving the effects of different wavebands of electromagnetic radiation on a cellular and organismal level. With my long-time professor and mentor, Dr. Sir Christopher S. Lange, SB (MIT), DPhil (Fac Med, Oxon), KCOM, we have defined the pathophysiology of Human Herpes Virus (HHV) reactivation in radiotherapy patients (PMID: 29197712) and defined the Organ at Risk (OAR) for development of sexual toxicities associated with prostatic irradiation (PMID: 32322175, 32549795 and 32536830). More recently, as President and Chief Executive Officer at BioFort, my investigational focus involves the development of patented lesional microdosimetry, fractionation and dose optimization for the radiopharmaceutical targeting of a variety of cell surface receptors (i.e., Molecular Brachytherapy).